Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Depreciation and Depletion (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Depreciation and Depletion for 6 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion rose 8.33% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, up 8.33% year-over-year, with the annual reading at $5.2 million for FY2025, 8.33% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $1.3 million at 4D Molecular Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • The five-year high for Depreciation and Depletion was $1.3 million in Q4 2023, with the low at $400000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $925000.0, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Depreciation and Depletion soared 150.0% in 2022, then dropped 7.69% in 2024.
  • Over 5 years, Depreciation and Depletion stood at $400000.0 in 2021, then skyrocketed by 150.0% to $1.0 million in 2022, then rose by 30.0% to $1.3 million in 2023, then dropped by 7.69% to $1.2 million in 2024, then grew by 8.33% to $1.3 million in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $1.3 million, $1.3 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.